Correlation of Serum and Salivary Cytokines Level With Clinical Parameters in Metabolic Syndrome With Periodontitis

Chauhan, Abhishek; Yadav, Suraj Singh; Dwivedi, Pradeep; Lal, Nand; Usman, Kauser; Khattri, Sanjay

doi:10.1002/jcla.21917

Cited by 33 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, our results showed that there were no correlation of salivary TNF‐α concentrations with other clinical parameters of gCP patients in both melatonin and placebo subjects. This comes in accordance with other studies; however, Chauhan et al results indicated the opposite in chronic periodontitis patients suffering from metabolic syndrome.…”

Section: Discussionsupporting

confidence: 92%

Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis?—A randomized controlled clinical trial

El-Sharkawy

Elmeadawy

El-Shinnawi

et al. 2018

J of Periodontal Research

View full text Add to dashboard Cite

Background and Objective Melatonin is synthesized naturally by pineal gland and responsible for regulation of sleep/waking cycle. It showed appreciated anti‐inflammatory and antioxidant properties. The aim of this randomized clinical trial (RCT) was to assess the additive effect of melatonin supplementation in insomniac individuals with generalized chronic periodontitis (gCP) after scaling and root planing (SRP). Material and Methods Seventy‐four gCP patients with primary insomnia participated in this 6‐month RCT and randomized into two groups. Melatonin group included 38 patients who were subjected to SRP with a 2‐month regimen of 10 mg oral melatonin capsule once daily before bedtime. In the control group, SRP was performed for 36 participants provided with matching placebo capsules. The primary treatment outcome was the measurement of clinical attachment level gain (CAL gain) after 3 and 6 months of therapy, whereas the measurements of pocket depth reduction (PD reduction), bleeding on probing (BOP %), and the changes in salivary TNF‐α levels and Athens insomnia scale (AIS) scores represented the secondary endpoints. Results Melatonin group showed significantly greater CAL gain and PD reduction measurements compared to the control group at 3 and 6 months of therapy, P < 0.01. Likewise, salivary TNF‐α levels and AIS scores were significantly lower in the melatonin group compared to placebo group. BOP% improved significantly in both groups without any difference. However, salivary TNF‐α levels exhibited no correlation with other clinical variables in both melatonin and placebo groups. Conclusion Daily dietary 10 mg of melatonin supplementation might serve as a viable adjunct to SRP that yielded significantly greater CAL gain and PD reduction and lower salivary TNF‐α levels and AIS scores in gCP patients with primary insomnia.

show abstract

Section: Discussionsupporting

confidence: 92%

Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis?—A randomized controlled clinical trial

El-Sharkawy

Elmeadawy

El-Shinnawi

et al. 2018

J of Periodontal Research

View full text Add to dashboard Cite

show abstract

“…Saliva is now regarded as a pool of biological markers and therefore has great potential for use in the prediction and diagnosis of systemic and localized diseases [ 30 ]. Many researchers have attempted to find useful biomarkers such as TNF- α , IL-10, IL-17, IL-12, and IL-1 β [ 10 , 31 – 33 ] in saliva that are associated with periodontitis to help predict or diagnose T2DM. However, low expression biomarkers are easily affected by systemic health status, which prevents these immunological markers from being widely employed [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Associations of Salivary BPIFA1 Protein in Chronic Periodontitis Patients with Type 2 Diabetes Mellitus

Guo

Zhu

et al. 2017

International Journal of Endocrinology

View full text Add to dashboard Cite

Aims To explore the differences in salivary BPI fold containing family A, member 1 (BPIFA1) concentration among type 2 diabetes mellitus (T2DM) subjects with various severities of chronic periodontitis and to determine whether BPIFA1 in saliva can be used as a potential biomarker of T2DM. Methods Unstimulated saliva samples were collected from 44 subjects with T2DM and 44 without T2DM (NDM). Additionally, demographic data and general health parameters, including fasting blood glucose (FBG) and body mass index (BMI), were collected. We also detected full-mouth clinical periodontal parameters including probing pocket depth (PPD), clinical attachment level (CAL), bleeding index (BI), and plaque index (PLI). Salivary BPIFA1, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) concentrations were also detected. Results BPIFA1 in saliva was detected at relatively high levels. T2DM subjects had decreased salivary BPIFA1 concentrations (P = 0.031). In T2DM subjects with nonperiodontitis or severe periodontitis, the level of BPIFA1 was significantly lower compared with that of NDM. Salivary TNF-α concentration displayed a similar trend to BPIFA1 in the NDM group. Conclusions BPIFA1 protein is rich in saliva and might be used as a potential predictive biomarker of T2DM, especially in patients with severe periodontitis and nonperiodontitis. This trial is registered with ChiCTR-ROC-17010310.

show abstract

“…(47) We also decided to estimate the afore-mentioned cytokines in unstimulated saliva because collection of saliva is a non invasive method and easily harvested in large amount and reflects all soluble mediators and cytokines in the periodontal tissues as most of the gingival sulcular fluid seeps into saliva. (48) To the best of our knowledge, there is no studies available until now investigating the salivary RANKL levels in chronic periodontitis patients who are maintained on a daily stable dose of statins. However, El-Sharkawy et al, 2010, assessed salivary RANKL in periodontitis patients after supplementation with omega-3 fatty acids combined with low dose of aspirin and demonstrated greater reduction in salivary RANKL when compared to the non-omega-3 E.D.J.…”

Section: Discussionmentioning

confidence: 99%

Does Atorvastatin Alone Ameliorate Chronic Periodontitis in Hyperlipidemic Patients? (A Cross-Sectional Study)

El-Sharkawy

Felemban

Manjunatha

2018

Egyptian Dental Journal

View full text Add to dashboard Cite

The present study was conducted to assess whether atorvastatin (ATV) alone could improve periodontal parameters and reduce inflammation and bone resorption in generalized chronic periodontitis (gCP) patients with hyperlipidemia. One hundred and two subjects were classified into three groups: Group I included 34 gCP patients with hyperlipidemia and maintained on a daily dose of 20 mg atorvastatin at least for 6 months. Group II comprised 34 gCP patients with hyperlipidemia and not taking any hypolipidemic drugs. Group III consisted of 34 normolipidemic individuals with gCP. The periodontal parameters including plaque index (PI), bleeding on probing (BOP), gingival index (GI), probing depth (PD) and clinical attachment loss (CAL) were recorded and compared. Unstimulated whole saliva and blood samples were harvested from all subjects. Salivary levels of interleukin-1beta (IL-1β) and receptor activator of nuclear kappa B ligand (RANKL) were evaluated by enzyme-linked immunosorbent assay (ELISA) technique. The blood samples were used to assess the lipid profile for all patients including total cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoproteincholesterol (HDL-C). The results demonstrated significantly greater decrease of periodontal parameters and salivary IL-1β and RANKL levels in group I compared to other groups. BOP, PD and CAL were positively correlated with the levels of salivary IL-1β, TC, TG and LDL-C whereas HDL-C measurements were negatively associated with BOP, PD and CAL. In conclusion, ATV could be a viable therapeutic modality in gCP management, due to its anti-inflammatory and antiosteopathic effects. Salivary IL-1β and RANKL could serve as reliable biomarkers in periodontal disease.

show abstract

Correlation of Serum and Salivary Cytokines Level With Clinical Parameters in Metabolic Syndrome With Periodontitis

Abstract: Proinflammatory marker TNF-α has correlation with clinical parameters in patients of MS having PD. The study suggests level of salivary TNF-α may be utilized as a surrogate marker of MS and PD.

Cited by 33 publications

References 30 publications

Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis?—A randomized controlled clinical trial

Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis?—A randomized controlled clinical trial

Associations of Salivary BPIFA1 Protein in Chronic Periodontitis Patients with Type 2 Diabetes Mellitus

Does Atorvastatin Alone Ameliorate Chronic Periodontitis in Hyperlipidemic Patients? (A Cross-Sectional Study)

Contact Info

Product

Resources

About